Newamsterdam Pharma Company Nv (NAMS)

$17.74

-0.01

(-0.06%)

Market is closed - opens 7 PM, 09 Oct 2024

Performance

  • $17.41
    $18.02
    $17.74
    downward going graph

    1.86%

    Downside

    Day's Volatility :3.39%

    Upside

    1.55%

    downward going graph
  • $5.63
    $26.35
    $17.74
    downward going graph

    68.25%

    Downside

    52 Weeks Volatility :78.62%

    Upside

    32.68%

    downward going graph

Returns

PeriodNewamsterdam Pharma Company NvIndex (Russel 2000)
3 Months
-11.3%
0.0%
6 Months
-6.39%
0.0%
1 Year
128.9%
0.0%
3 Years
71.4%
-20.8%

Highlights

Market Capitalization
1.6B
Book Value
$4.3
Earnings Per Share (EPS)
-2.62
Wall Street Target Price
37.0
Profit Margin
0.0%
Operating Margin TTM
-2306.93%
Return On Assets TTM
-27.15%
Return On Equity TTM
-54.08%
Revenue TTM
7.4M
Revenue Per Share TTM
0.09
Quarterly Revenue Growth YOY
32.7%
Gross Profit TTM
0.0
EBITDA
-208.6M
Diluted Eps TTM
-2.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.44
EPS Estimate Next Year
-1.74
EPS Estimate Current Quarter
-0.58
EPS Estimate Next Quarter
-0.51

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Newamsterdam Pharma Company Nv(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 108.57%

Current $17.74
Target $37.00

Technicals Summary

Sell

Neutral

Buy

Newamsterdam Pharma Company Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Newamsterdam Pharma Company Nv
Newamsterdam Pharma Company Nv
5.09%
-6.39%
128.9%
71.4%
71.4%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.19%
6.5%
20.85%
84.03%
245.65%
Novo Nordisk A/s
Novo Nordisk A/s
-11.15%
-6.13%
27.31%
138.21%
354.53%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
5.38%
73.95%
61.12%
32.59%
252.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.58%
13.46%
29.21%
155.56%
172.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Newamsterdam Pharma Company Nv
Newamsterdam Pharma Company Nv
30.14
NA
NA
-2.44
-0.54
-0.27
NA
4.3
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.37
26.37
1.36
45.03
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.76
38.76
1.75
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.54
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Newamsterdam Pharma Company Nv
Newamsterdam Pharma Company Nv
Buy
$1.6B
71.4%
30.14
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$109.8B
245.65%
26.37
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$512.4B
354.53%
38.76
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.2B
252.19%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.8B
172.0%
32.84
-4.74%

Insights on Newamsterdam Pharma Company Nv

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.29M → 2.12M (in $), with an average increase of 39.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -86.89M → -36.41M (in $), with an average increase of 138.6% per quarter

Institutional Holdings

  • FCPM III SERVICES BV

    13.14%
  • Bain Capital Life Sciences Investors, LLC

    11.64%
  • RA Capital Management, LLC

    8.96%
  • Viking Global Investors LP

    8.91%
  • Medicxi Ventures Management (Jersey) Ltd

    3.19%
  • Cormorant Asset Management, LLC

    2.56%

Company Information

Organization
Newamsterdam Pharma Company Nv
Employees
57
CEO
Dr. Michael Harvey Davidson FACC, Facp., M.D.
Industry
Miscellaneous

FAQs